Thursday November 19, 2020 0 comments
AURORA -- Summit Biolabs, an early-stage molecular diagnostics company specializing in saliva liquid-biopsy tests for COVID-19 and head and neck cancer, announced it received funding from the University of Colorado Anschutz Medical Campus (CU Anschutz), Chancellor Discovery Innovation Fund (CDI Fund).
University of Colorado Anschutz Medical Campus Chancellor Don Elliman congratulated Summit Biolabs, describing the selection process by an external review board as "highly competitive and gives the funding the utmost honor and prestige."
The amount of the Summit investment was not disclosed.
The CDI Fund focuses on supporting healthcare technologies that are addressing unmet clinical needs with translational gap funding. The funds are deployed to support specific milestone-based objectives with the intention of unlocking future development or commercial opportunities.
The fund is opportunistic in nature and will fund projects on a rolling basis.
"We are honored to receive this esteemed investment from CDI Fund," said Bob Blomquist, CEO at Summit Biolabs. "This will help strengthen Summit Biolabs' ability to bring to market life-changing saliva liquid-biopsy tests that ultimately enable better treatment and improved outcomes for patients."
Founded on the discoveries of Dr. Shi-Long Lu, Summit Biolabs is being spun out from the University of Colorado Anschutz Medical Campus.
Summit Biolabs is pioneering early detection of head & neck cancer recurrence using a first of its kind saliva liquid-biopsy test, HNKlear.
HNKlear is a proprietary, non-invasive saliva test that provides more effective, more accurate, and earlier detection of head and neck cancer recurrence than traditional diagnostic methods.